Cancer Immunotherapy Via Dendritic Cells

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2012 Mar 23

PMID 22437871

Citations 926

Authors

Karolina Palucka

Jacques Banchereau

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy attempts to harness the power and specificity of the immune system to treat tumours. The molecular identification of human cancer-specific antigens has allowed the development of antigen-specific immunotherapy. In one approach, autologous antigen-specific T cells are expanded ex vivo and then re-infused into patients. Another approach is through vaccination; that is, the provision of an antigen together with an adjuvant to elicit therapeutic T cells in vivo. Owing to their properties, dendritic cells (DCs) are often called 'nature's adjuvants' and thus have become the natural agents for antigen delivery. After four decades of research, it is now clear that DCs are at the centre of the immune system owing to their ability to control both immune tolerance and immunity. Thus, DCs are an essential target in efforts to generate therapeutic immunity against cancer.

Citing Articles

Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.

Bikorimana J, Farah R, Abusarah J, Mandl G, Erregragui M, Goncalves M iScience. 2025; 28(3):111957.

PMID: 40060894 PMC: 11889607. DOI: 10.1016/j.isci.2025.111957.

Hypoxic tumor cell line lysate-pulsed dendritic cell vaccine exhibits better therapeutic effects on hepatocellular carcinoma.

Jeng L, Shih F, Liao Y, Shyu W, Teng C Br J Cancer. 2025; .

PMID: 40050434 DOI: 10.1038/s41416-025-02975-w.

Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.

Zhao C, Jia B, Jiang Y, Shike H, Annageldiyev C, Cioccio J Cancer Immunol Immunother. 2025; 74(4):117.

PMID: 39998689 PMC: 11861774. DOI: 10.1007/s00262-025-03971-y.

Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells.

Cai P, Sun H, Jiang T, Li H, Huang D, Hao X Cancer Immunol Immunother. 2025; 74(4):114.

PMID: 39998561 PMC: 11861500. DOI: 10.1007/s00262-025-03960-1.

GATA3-Driven ceRNA Network in Lung Adenocarcinoma Bone Metastasis Progression and Therapeutic Implications.

Liu Y, Shen S, Wang X, Chen H, Ren W, Wei H Cancers (Basel). 2025; 17(3).

PMID: 39941924 PMC: 11816722. DOI: 10.3390/cancers17030559.

References

Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher G . Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001; 98(15):8809-14. PMC: 37517. DOI: 10.1073/pnas.141226398. View

Zapata-Gonzalez F, Rueda F, Petriz J, Domingo P, Villarroya F, de Madariaga A . 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and.... J Immunol. 2007; 178(10):6130-9. DOI: 10.4049/jimmunol.178.10.6130. View

Nair S, Morse M, Boczkowski D, Cumming R, Vasovic L, Gilboa E . Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002; 235(4):540-9. PMC: 1422470. DOI: 10.1097/00000658-200204000-00013. View

Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez R, Wang Y . Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science. 2010; 329(5993):849-53. PMC: 3732486. DOI: 10.1126/science.1188510. View

Bousso P, Robey E . Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol. 2003; 4(6):579-85. DOI: 10.1038/ni928. View

Gaucher D, Therrien R, Kettaf N, Angermann B, Boucher G, Filali-Mouhim A . Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008; 205(13):3119-31. PMC: 2605227. DOI: 10.1084/jem.20082292. View

Chen L, Ashe S, Brady W, Hellstrom I, Hellstrom K, Ledbetter J . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71(7):1093-102. DOI: 10.1016/s0092-8674(05)80059-5. View

Zhang N, Bevan M . CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011; 35(2):161-8. PMC: 3303224. DOI: 10.1016/j.immuni.2011.07.010. View

10.

Hoos A, Eggermont A, Janetzki S, Hodi F, Ibrahim R, Anderson A . Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010; 102(18):1388-97. PMC: 2943524. DOI: 10.1093/jnci/djq310. View

11.

Hashimoto D, Miller J, Merad M . Dendritic cell and macrophage heterogeneity in vivo. Immunity. 2011; 35(3):323-35. PMC: 4520532. DOI: 10.1016/j.immuni.2011.09.007. View

12.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

13.

Holtl L, RIESER C, Papesh C, Ramoner R, Herold M, Klocker H . Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999; 161(3):777-82. View

14.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

15.

Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T . Dendritic cell subsets in health and disease. Immunol Rev. 2007; 219:118-42. DOI: 10.1111/j.1600-065X.2007.00551.x. View

16.

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

17.

Batista F, Harwood N . The who, how and where of antigen presentation to B cells. Nat Rev Immunol. 2008; 9(1):15-27. DOI: 10.1038/nri2454. View

18.

Timmerman J, Czerwinski D, Davis T, Hsu F, Benike C, Hao Z . Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002; 99(5):1517-26. DOI: 10.1182/blood.v99.5.1517. View

19.

Pulendran B, Li S, Nakaya H . Systems vaccinology. Immunity. 2010; 33(4):516-29. PMC: 3001343. DOI: 10.1016/j.immuni.2010.10.006. View

20.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View